Multiple Myeloma Clinical Trial
Descartes-11 in Multiple Myeloma
This Phase I/2 study will test the safety and anti-myeloma activity of ascending doses of Descartes-11 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
Active multiple myeloma that is refractory after at least 2 prior lines of therapy;
adequate vital organ function; and
no active infection.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 2 Locations for this study
Bethesda Maryland, 20817, United States
Madison Wisconsin, 53226, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.